Biological
PNK-007
PNK-007 is a biological therapy with 2 clinical trials. Historical success rate of 50.0%.
Total Trials
2
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(50%)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Terminated(1)
Detailed Status
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
completed150%
terminated150%
Recent Activity
0 active trials
Showing 2 of 2
terminatedphase_1
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
NCT02781467
completedphase_1
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
NCT02955550
Clinical Trials (2)
Showing 2 of 2 trials
NCT02781467Phase 1
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
NCT02955550Phase 1
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
All 2 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 2